Repligen Co. (NASDAQ:RGEN - Free Report) - William Blair decreased their Q2 2025 earnings per share (EPS) estimates for shares of Repligen in a research note issued to investors on Wednesday, April 30th. William Blair analyst M. Larew now forecasts that the biotechnology company will earn $0.41 per share for the quarter, down from their prior forecast of $0.45. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen's Q3 2025 earnings at $0.40 EPS, Q4 2025 earnings at $0.46 EPS, Q1 2026 earnings at $0.49 EPS and Q2 2026 earnings at $0.57 EPS.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. During the same period in the prior year, the firm posted $0.28 EPS. The company's revenue was up 10.4% on a year-over-year basis.
Several other research firms have also weighed in on RGEN. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Monday. Canaccord Genuity Group cut their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research note on Wednesday, April 16th. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. Evercore ISI assumed coverage on Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $173.25.
Check Out Our Latest Report on RGEN
Repligen Stock Performance
Shares of Repligen stock opened at $137.99 on Thursday. The firm has a market cap of $7.75 billion, a PE ratio of -270.57, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The firm's 50-day simple moving average is $138.77 and its 200-day simple moving average is $145.87. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a 1 year low of $102.97 and a 1 year high of $182.52.
Institutional Trading of Repligen
Several hedge funds and other institutional investors have recently modified their holdings of RGEN. Signaturefd LLC raised its position in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new position in Repligen during the fourth quarter worth $29,000. Raiffeisen Bank International AG bought a new stake in Repligen in the 4th quarter valued at about $29,000. Itau Unibanco Holding S.A. bought a new stake in Repligen in the 4th quarter valued at about $40,000. Finally, Center for Financial Planning Inc. increased its holdings in Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 193 shares in the last quarter. Institutional investors own 97.64% of the company's stock.
Insider Activity at Repligen
In related news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is owned by insiders.
About Repligen
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
